Key Players
Competitive Landscape
Competition is moving away from basic powder availability toward controlled composition and application support. Stratum Nutrition and ESM Technologies compete with established branded platforms such as NEM and OVOLUX. Biova differentiates through water-soluble egg membrane technology, Eggnovo combines membrane processing with regulatory and distribution expansion, and Kewpie brings long-standing egg-processing capabilities into both powdered and hydrolyzed formats. Certified Nutraceuticals and Seno Biotech widen the supply base through specialized collagen and egg-derived ingredient routes.
The commercial barrier is the ability to keep the material in the specification aligned with the material used in the supporting safety, quality and efficacy package. Buyers increasingly compare protein and collagen ranges, solubility, microbiological controls, allergen management, country-specific use conditions and formulation support. Suppliers that shorten this qualification work can defend higher-value positions even when competing powders are available at lower prices.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| July 2026: Eggnovo became the named applicant under the EU authorization for enzymatically produced egg membrane hydrolysate. | Brand owners need clearer regulatory routes for differentiated membrane ingredients. | Regulatory specificity is becoming part of product differentiation. | Support adult food-supplement launches with a defined hydrolyzed ingredient specification. |
| September 2025: Stratum Nutrition opened a new operational facility in Carthage, Missouri, supporting NEM and OVOLUX demand. | Growing branded-ingredient demand requires faster logistics and operating capacity. | Leading suppliers are investing behind proprietary ESM platforms. | Improve response time and support wider joint-health and beauty-from-within programs. |
| August 2025: Biova updated BiovaPlex with guaranteed minimum levels of collagen, elastin and glycosaminoglycans. | Formulators want tighter compositional certainty from natural membrane ingredients. | Standardization is becoming more important than generic source claims. | Use defined bioactive levels to support premium pet-health and adjacent formulation programs. |
| May 2025: Eggnovo and IQI partnered to distribute Ovopet in North America. | Ingredient suppliers need regional commercial access and formulation support. | Branded ESM platforms are using specialist distributors to expand reach. | Accelerate co-development and adoption in North American pet nutrition. |
The competitive pattern favors suppliers that pair processing control with a market-ready technical package. Capacity expansion, tighter compositional guarantees and regional distribution are all aimed at reducing the work a formulator must do before moving from a sample to a repeat order.
Which companies have the clearest direct eggshell membrane positioning?
Stratum Nutrition, ESM Technologies, Biova, Eggnovo and Kewpie each market direct eggshell membrane ingredients in powdered, partially hydrolyzed or water-soluble forms. Their differentiation comes from processing method, supporting data, format flexibility and commercial reach.
What qualification evidence do buyers need before purchasing eggshell membrane powder?
Buyers typically compare ingredient identity, protein and collagen specifications, hydrolysis or solubility state, allergen controls, microbiological limits and batch consistency. They also need the proposed use and claims to fit the regulatory pathway in the target country.
Which suppliers show recent investment or commercial expansion relevant to the market?
Stratum Nutrition expanded operating capacity in Missouri and European commercial support during 2025. Eggnovo gained a 2026 EU novel-food authorization for a defined hydrolyzed membrane ingredient and expanded North American distribution through IQI. Biova tightened the specification of its BiovaPlex membrane ingredient in 2025.
How does geographic reach differ across the profiled companies?
Stratum Nutrition and ESM Technologies combine United States operations with international commercialization. Eggnovo is based in Spain and has expanded distribution into North America. Kewpie anchors a major Japanese egg-derived ingredient platform, while Biova and Certified Nutraceuticals operate from North American bases and Seno Biotech serves Asian and international ingredient channels.
Representative Company Overview
| Company | Positioning | Recent Direct Evidence |
|---|---|---|
| Stratum Nutrition | Branded eggshell membrane ingredients for joint health and beauty-from-within, supported by formulation and regulatory programs. | September 2025: opened a new Carthage operational facility supporting demand for NEM and OVOLUX. |
| ESM Technologies, LLC | U.S. manufacturing and technical platform behind partially hydrolyzed eggshell membrane ingredients. | February 2025: FDA closed GRN No. 1194 at the notifier's request for a proposed partially hydrolyzed eggshell membrane food ingredient. |
| Eggnovo S.L. | Spanish eggshell-membrane specialist supplying Ovomet and related functional ingredients. | July 2026: named applicant under EU authorization 2026/1427 for enzymatically produced egg membrane hydrolysate. |
| Biova LLC | Water-soluble egg membrane specialist serving human and animal health formulations. | August 2025: introduced guaranteed minimum levels of collagen, elastin and glycosaminoglycans for BiovaPlex. |
| Kewpie Corporation | Integrated egg-derived ingredient supplier offering EM POWDER (300) and hydrolyzed EMlastic formats. | 2025: Kewpie's R&D publications included work involving hydrolyzed eggshell membrane, reinforcing its active egg-membrane research platform. |
| Seno Biotech | Egg-derived bioactive ingredient platform with an eggshell membrane product for joint mobility and skin-care positioning. | October 2025: the company reported a frontier technology award for eggshell membrane nutrition research. |
Research Methodology
Company analysis covers suppliers with current eggshell membrane products, direct processing capability or documented branded ingredient platforms within the defined market. Competitive benchmarking considers product depth, soluble or hydrolyzed format capability, clinical or regulatory support and geographic reach. Company developments use dated 2025-2026 regulatory records, official announcements and current product information. The benchmarking is capability-based and does not present company market shares.
